The Enterprise Value as of November 2024 (TTM) for NovAccess Global Inc. (XSNX) is 2.65M

According to NovAccess Global Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.65M. This represents a change of -12.55% compared to the average of 3.03M of the last 4 quarters.

NovAccess Global Inc. (XSNX) Historical Enterprise Value (quarterly & annually)

How has XSNX Enterprise Value performed in the past?

The mean historical Enterprise Value of NovAccess Global Inc. over the last ten years is 2.78M. The current 2.65M Enterprise Value has changed 9.43% with respect to the historical average. Over the past ten years (40 quarters), XSNX's Enterprise Value was at its highest in in the June 2021 quarter at 9.75M. The Enterprise Value was at its lowest in in the June 2020 quarter at 537.72K.

NovAccess Global Inc. (XSNX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of NovAccess Global Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

NovAccess Global Inc. (XSNX) Average Enterprise Value

How has XSNX Enterprise Value performed in the past?

The current Enterprise Value of NovAccess Global Inc. (XSNX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

NovAccess Global Inc. (XSNX) Enterprise Value vs. Peers

How is XSNX’s Enterprise Value compared to its peers?

NovAccess Global Inc.’s Enterprise Value is less than Novo Nordisk A/S (3.35T), less than Cellectis S.A. (115.55M), less than Biotron Limited (16.98M), less than Covalon Technologies Ltd. (93.17M), greater than Bioasis Technologies Inc. (397.14K), less than Mosaic ImmunoEngineering Inc. (8.29M), less than EPIRUS Biopharmaceuticals, Inc. (0), less than ImmunoCellular Therapeutics, Ltd. (19.26M), less than VG Life Sciences Inc. (3.17M), less than Genenta Science S.p.A. (78.68M), less than Lumos Pharma, Inc. (23.89M), less than Marker Therapeutics, Inc. (18.66M), less than Exicure, Inc. (45.02M), less than Protagenic Therapeutics, Inc. (3.36M), less than PMV Pharmaceuticals, Inc. (47.77M),

Build a custom stock screener for NovAccess Global Inc. (XSNX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NovAccess Global Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

NovAccess Global Inc. (XSNX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like NovAccess Global Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.